glp-1 drugs canada WHO backs meds to treat obesity, but many Islanders can't access them 3 million Canadians use GLP-1

It is essential to disclose all medications, including any GLP-1 agonists, as these may influence symptom assessment and disease monitoring

In 2014, the FDA and the EMA found no causal association between GLP-1RA and pancreatic adverse events (67)

The condition resolved after discontinuing liraglutide and using topical triamcinolone, leaving only post-inflammatory hyperpigmentation [60, 80]

Several large-scale RCTs and meta-analyses have reported no statistically significant increase in pancreatitis risk associated with GLP-1 RAs

What is a GLP- 1 Agonist and how do they work

While its a tall order, its achievable given the pace at which the market is growing